Flupentixol/melitracen (trade name Deanxit, Placida, Franxit, Anxidreg, Danxipress) is a combination of two psychoactive agents (a typical antipsychotic drug of the thioxanthene class) and tricyclic antidepressant (TCA)) which has antidepressant properties. It is designed for short term usage only. It is produced by Lundbeck.
Flupentixol/melitracen were banned in India by the country's Ministry of Health and Family Welfare on July 11, 2014, after the government noted it was not approved for marketing in several developed markets including the United States, UK, Canada, Japan, Australia, or even in its country of origin, Denmark. Lundbeck plans to take legal action to have the ban lifted. It is being marketed in China, Taiwan, Thailand and a few European countries.
Other Brand names
Brand names include:
- Pentoxol.m (scotmann pharmaceuticals pakistan)
- Sensit (Eskayef Bangladesh Ltd.)
- Renxit (Renata Ltd.)
- Melixol (Square Pharmaceuticals Ltd.)
- Melanxit (Organic Health Care Ltd.)
- Benzit (Bio-Pharma Ltd.)
- Leanxit (ACME Laboratories Ltd.)
- Danxipress (Vickmans Lab Ltd.)
- Sweetman, Sean C., ed. (2009). "Preparations". Martindale: The complete drug reference (36th ed.). London: Pharmaceutical Press. p. 2607. ISBN 978-0-85369-840-1.
- "Ministry of Health and Family Welfare (Department of Health and Family Welfare) Notification, New Delhi" (PDF). The Gazette of India. July 11, 2014. Retrieved March 19, 2015 – via drugscontrol.org.
- Soma Das, ET Bureau (July 25, 2014). "Lundbeck to seek legal recourse after health ministry bans Deanxit again". Economic Times. Retrieved March 19, 2015.
- "Drugs.com entry for Deanxit". Archived from the original on 2016-05-22. Retrieved 2019-01-26.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|